



*TSX Venture Exchange: CCG
FOR IMMEDIATE RELEASE*

CardioComm Solutions Inc. Announces Q1, 2005 Financial Report

VICTORIA, B.C., May 27, 2005– CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), today announced its financial results for the first quarter ended March 31, 2005. Please refer to the Company's financial statements and management's discussion & analysis filed electronically at www.sedar.com.

Commenting on the results, Stephen Martin, CEO said "Today we announced our Q1 results. While the results are lower than the comparable period last year, we have seen the sales pipeline increase in the second and subsequent quarters. The recently announced agreements with Lumedx and the newly announced GlobalCardio Enterprise product line as well as the resumption of critical co-development software orders will be recognized in ensuing quarters. We expect that fiscal 2005 will be a very good year of growth".

Revenues for the first quarter of 2005 were \$219,011 compared to \$787,079 for the first quarter of 2004. This \$567,168 (72%) decrease in revenue over the same period 2004 is due to a temporarily diminished custom solutions development workload. CardioComm recorded a net loss of \$413,037 for the first quarter 2005 as compared to a net profit of \$32,134 in the same period last year.

General and Administrative expenditures were \$207,010 in the first quarter of 2005 as compared to \$259,110 in the same period last year. The expenses decreased by \$52,100 (20%). This substantial change was due to a large decrease in stock compensation expense of \$42,489.

During the first quarter, Sales and Marketing expenditures were \$137,622 as compared to \$212,857 in the same period last year. The expenses decreased by \$75,235 (35%) for the first quarter of 2005 compared to the same period last year. The decrease in costs result from cost containment initiatives, and a decrease in various sales related expenses such as commissions.

About CardioComm Solutions Inc:

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors
of CardioComm Solutions Inc.:

“Stephen Martin”

Stephen R. Martin, President & CEO

***For investor information, please
contact:***

Derek Sutherland

IR@CardioComm.com

Call 1-416-832-0442

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this release.